Swiss drugmaker Roche has won approval from U.S. antitrust authorities for its $4.3 billion bid to acquire gene therapy specialist Spark Therapeutics. The development clears the way for Roche’s strategic push to position itself in the treatment of rare diseases,… Read More ›